YONKERS, N.Y., Sept. 06, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody ...

Expert Rev Anti Infect Ther. 2009;7(8):967-980. Nafcillin is considered the intravenous treatment of choice for MSSA; however, many other intravenous agents such as cephalosporins, β-lactams and ...

A large multi-state study by the Centers for Disease Control and Prevention, the Harvard Pilgrim Health Care Institute, HCA Healthcare, and the University of California, Irvine has found that a nasal ...

Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window An early switch to oral antibiotics in patients hospitalized ...

During IDWeek 2025 in Atlanta, Georgia, Loren G. Miller, MD, MPH, investigator at The Lundquist Institute for Biomedical ...

Patient-to-patient transmission accounts for less than one-quarter of in-hospital cases of Staphylococcus aureus, which means traditional patient-centered infection control practices for stopping the ...

Patients staying in hospital rooms with multiple beds are at an increased risk — up to ninefold higher — for Staphylococcus ...

Results from a study published in Infection Control and Hospital Epidemiology suggest Staphylococcus aureus colonization is not linked to mortality among patients infected with MRSA. Researchers ...

A Bacillus subtilis probiotic demonstrated the ability to wipe out most Staphylococcus aureus colonization without altering the gut microbiome, a placebo-controlled phase II study conducted in ...

Scientists have demonstrated for the first time how Staphylococcus aureus—a leading cause of skin infections—reshapes the ...